GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'

 
• By Sten Stovall

GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.

Myeloma
GSK's monoclonal ADC GSK2857916 wins FDA breakthrough status in multiple myeloma • Source: Shutterstock

More from Clinical Trials

More from R&D